Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan

References

• Pugner KM, Scott DI, Holmes JW, Hieke K. The costs of rheumatoid arthritis: an international long-term view. Semin Arthritis Rheum. 2000;29:305–20.
   PubMed Web of Science ®Google Scholar
• Yelin E, Murphy L, Cisternas MG, Foreman AJ, Pasta DJ, Helmick CG. Medical care expenditures and earnings losses among persons with arthritis and other rheumatic conditions in 2003, and comparisons with 1997. Arthritis Rheum. 2007;56:1397–407.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Inoue E, Mannalithara A, Bennett M, Kamitsuji S, Taniguchi A, et al. Medical care costs of patients with rheumatoid arthritis during the prebiologics period in Japan: a large prospective observational cohort study. Mod Rheumatol. 2010;20:46–53.
   PubMed Web of Science ®Google Scholar
• Michaud K, Messer J, Choi HK, Wolfe F. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. Arthritis Rheum. 2003;48:2750–62.
   PubMed Web of Science ®Google Scholar
• Beresniak A, Gossec L, Goupille P, Saraux A, Bamberger M, Bregman B, et al. Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France. J Rheumatol. 2011;38:439–45.
   PubMed Web of Science ®Google Scholar
• Kobelt G, Woronoff AS, Richard B, Peeters P, Sany J. Disease status, costs and quality of life of patients with rheumatoid arthritis in France: the ECO-PR Study. Joint Bone Spine. 2008;75:408–15.
   PubMed Web of Science ®Google Scholar
• Tanaka E, Hoshi D, Igarashi A, Inoue E, Shidara K, Sugimoto N, et al. Analysis of direct medical and nonmedical costs for care of rheumatoid arthritis patients using the large cohort database, IORRA. Mod Rheumatol. 2013;23:742–51.
   PubMed Web of Science ®Google Scholar
• Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ. 2012;15:340–51.
   PubMedGoogle Scholar
• Diamantopoulos A, Benucci M, Capri S, Berger W, Wintfeld N, Giuliani G, et al. Economic evaluation of tocilizumab combination in the treatment of moderate-to-severe rheumatoid arthritis in Italy. J Med Econ. 2012;15:576–85.
   PubMedGoogle Scholar
• Diamantopoulos A, Finckh A, Huizinga T, Sungher DK, Sawyer L, Neto D, et al. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. Pharmacoeconomics. 2014;32:775–87.
   PubMed Web of Science ®Google Scholar
• Beresniak A, Baerwald C, Zeidler H, Kruger K, Neubauer AS, Dupont D, et al. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany. Clin Exp Rheumatol. 2013;31:400–8.
   PubMed Web of Science ®Google Scholar
• Tran-Duy A, Boonen A, Kievit W, van Riel PL, van de Laar MA, Severens JL. Modelling outcomes of complex treatment strategies following a clinical guideline for treatment decisions in patients with rheumatoid arthritis. Pharmacoeconomics. 2014;32:1015–28.
   PubMed Web of Science ®Google Scholar
• Wu B, Wilson A, Wang FF, Wang SL, Wallace DJ, Weisman MH, et al. Cost effectiveness of different treatment strategies in the treatment of patients with moderate to severe rheumatoid arthritis in china. PLoS One. 2012;7:e47373. doi: http://dx.doi.org/10.1371/journal.pone.0047373.
   PubMedGoogle Scholar
• Yamanaka H, Tohma S. Potential impact of observational cohort studies in Japan on rheumatoid arthritis research and practice. Mod Rheumatol. 2006;16:75–6.
   PubMedGoogle Scholar
• Yamanaka H. A cohort study of clinical care in rheumatoid arthritis: the IORRA study. JMAJ. 2009;52:54–5.
   Google Scholar
• Tanaka E, Inoue E, Hoshi D, Shimizu Y, Kobayashi A, Sugimoto N, et al. Cost-effectiveness of tocilizumab, a humanized anti-interleukin-6 receptor monoclonal antibody, versus methotrexate in patients with rheumatoid arthritis using real-world data from the IORRA observational cohort study. Mod Rheumatol. 2015;25:503–13.
   PubMed Web of Science ®Google Scholar
• Siebert U, Alagoz O, Bayoumi AM, Jahn B, Owens DK, Cohen DJ, et al. State-transition modeling: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–3. Value Health. 2012;15:812–20.
   PubMed Web of Science ®Google Scholar
• Matsuda Y, Singh G, Yamanaka H, Tanaka E, Urano W, Taniguchi A, et al. Validation of a Japanese version of the Stanford Health Assessment Questionnaire in 3,763 patients with rheumatoid arthritis. Arthritis Rheum. 2003;49:784–8.
   PubMed Web of Science ®Google Scholar
• Shiroiwa T, Sung YK, Fukuda T, Lang HC, Bae SC, Tsutani K. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? Health Econ. 2010;19:422–37.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Inoue E, Tanaka E, Singh G, Sato E, Hoshi D, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. Scand J Rheumatol. 2010;39:360–7.
   PubMed Web of Science ®Google Scholar
• Abridged Life Tables for Japan 2010. Statistics and Information Department DMsS, Ministry of Health, Labour and Welfare; 2010. Available from: http://www.mhlw.go.jp/english/database/db-hw/lifetb10/ [last accessed 1 Dec 2014].
   Google Scholar
• Diagnostic Procedure Combination Comprehensive Evaluation 2010. 2010. Available from: http://www.mhlw.go.jp/bunya/iryouhoken/iryouhoken12/dl/setumei_15.pdf.
   Google Scholar
• Chapter 16 Labour and Wages. Japan Statistical Yearbook 2011. Available from: http://www.stat.go.jp/english/data/nenkan/back60/1431-16.htm [last accessed 1 Dec 2014].
   Google Scholar
• Shiroiwa T, Igarashi A, Fukuda T, Ikeda S. WTP for a QALY and health states: more money for severer health states? Cost Eff Resour Alloc. 2013;11:22. doi: 10.1186/1478-7547-11-22.
   PubMedGoogle Scholar
• Gabay C, Emery P, van Vollenhoven R, Dikranian A, Alten R, Pavelka K, et al. Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. Lancet. 2013;381:1541–50.
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis. 2008;67:1516–23.
   PubMed Web of Science ®Google Scholar